Published in Mol Cancer Ther on August 05, 2016
Association of high microvessel αvβ3 and low PTEN with poor outcome in stage 3 neuroblastoma: rationale for using first in class dual PI3K/BRD4 inhibitor, SF1126. Oncotarget (2016) 0.75
Downregulation of A20 increases the cytotoxicity of IFN-γ in hepatocellular carcinoma cells. Drug Des Devel Ther (2017) 0.75
The Protein Data Bank. Nucleic Acids Res (2000) 187.10
Sorafenib in advanced hepatocellular carcinoma. N Engl J Med (2008) 54.30
Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer (2014) 40.30
Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul (1984) 35.22
Selective inhibition of BET bromodomains. Nature (2010) 18.79
EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol (2012) 16.93
BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell (2011) 14.34
RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature (2011) 11.44
MYC on the path to cancer. Cell (2012) 8.65
Molecular targeted therapies in hepatocellular carcinoma. Hepatology (2008) 6.16
PI3K and cancer: lessons, challenges and opportunities. Nat Rev Drug Discov (2014) 4.81
PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. Oncogene (2005) 4.07
Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology (2008) 4.03
Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases. Cancer Res (2007) 3.09
BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia. Blood (2012) 2.91
Bromodomains as therapeutic targets. Expert Rev Mol Med (2011) 2.52
Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo. J Hepatol (2009) 2.42
A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity. Cancer Res (2008) 2.30
Expression and prognostic role of tumor suppressor gene PTEN/MMAC1/TEP1 in hepatocellular carcinoma. Cancer (2003) 2.09
Pathogenesis of hepatocellular carcinoma and molecular therapies. Curr Opin Gastroenterol (2009) 1.52
The mTOR pathway is associated with the poor prognosis of human hepatocellular carcinoma. Med Oncol (2009) 1.46
PI-103 and sorafenib inhibit hepatocellular carcinoma cell proliferation by blocking Ras/Raf/MAPK and PI3K/AKT/mTOR pathways. Anticancer Res (2010) 1.43
Sorafenib and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma. J Cell Mol Med (2009) 1.30
Targeting c-Myc as a novel approach for hepatocellular carcinoma. World J Hepatol (2010) 1.22
Kinase and BET Inhibitors Together Clamp Inhibition of PI3K Signaling and Overcome Resistance to Therapy. Cancer Cell (2015) 1.21
PKI-587 and sorafenib targeting PI3K/AKT/mTOR and Ras/Raf/MAPK pathways synergistically inhibit HCC cell proliferation. J Surg Res (2011) 1.15
Review article: pharmacological therapy for hepatocellular carcinoma with sorafenib and other oral agents. Aliment Pharmacol Ther (2008) 1.12
Phase I pharmacokinetic and pharmacodynamic study of the pan-PI3K/mTORC vascular targeted pro-drug SF1126 in patients with advanced solid tumours and B-cell malignancies. Eur J Cancer (2012) 1.11
The commonly used PI3-kinase probe LY294002 is an inhibitor of BET bromodomains. ACS Chem Biol (2013) 1.04
Clinical trials in hepatocellular carcinoma: an update. Liver Cancer (2013) 0.99
Hepatocyte growth factor promotes migration of human hepatocellular carcinoma via phosphatidylinositol 3-kinase. Clin Exp Metastasis (1999) 0.96
Sorafenib in advanced hepatocellular carcinoma. N Engl J Med (2008) 0.96
Targeted therapies: Role of sorafenib in HCC patients with compromised liver function. Nat Rev Clin Oncol (2009) 0.93
MDM2 regulates hypoxic hypoxia-inducible factor 1α stability in an E3 ligase, proteasome, and PTEN-phosphatidylinositol 3-kinase-AKT-dependent manner. J Biol Chem (2014) 0.92
A macrophage-dominant PI3K isoform controls hypoxia-induced HIF1α and HIF2α stability and tumor growth, angiogenesis, and metastasis. Mol Cancer Res (2014) 0.91
Novel molecular therapies in hepatocellular carcinoma. Liver Int (2011) 0.91
Suppression of BRD4 inhibits human hepatocellular carcinoma by repressing MYC and enhancing BIM expression. Oncotarget (2016) 0.87
Global and country underestimation of hepatocellular carcinoma (HCC) in 2012 and its implications. Cancer Epidemiol (2015) 0.85
Mechanisms of hepatocellular carcinoma and challenges and opportunities for molecular targeted therapy. World J Hepatol (2015) 0.84
BRD4 promotes tumor growth and epithelial-mesenchymal transition in hepatocellular carcinoma. Int J Immunopathol Pharmacol (2015) 0.82
Anti-tumor effect of a novel PI3-kinase inhibitor, SF1126, in (12) V-Ha-Ras transgenic mouse glioma model. Cancer Cell Int (2014) 0.81
PTEN and PI-3 kinase inhibitors control LPS signaling and the lymphoproliferative response in the CD19+ B cell compartment. Exp Cell Res (2014) 0.81
Pan-PI-3 kinase inhibitor SF1126 shows antitumor and antiangiogenic activity in renal cell carcinoma. Cancer Chemother Pharmacol (2015) 0.80
PI-3K Inhibitors Preferentially Target CD15+ Cancer Stem Cell Population in SHH Driven Medulloblastoma. PLoS One (2016) 0.79
Sorafenib for liver cancer: the horizon broadens. Lancet Oncol (2009) 0.78
Epigenetic reader BRD4 inhibition as a therapeutic strategy to suppress E2F2-cell cycle regulation circuit in liver cancer. Oncotarget (2016) 0.78